85 related articles for article (PubMed ID: 25906354)
1. Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication.
Gamberi T; Magherini F; Fiaschi T; Landini I; Massai L; Valocchia E; Bianchi L; Bini L; Gabbiani C; Nobili S; Mini E; Messori L; Modesti A
Mol Biosyst; 2015 Jun; 11(6):1653-67. PubMed ID: 25906354
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c).
Gamberi T; Massai L; Magherini F; Landini I; Fiaschi T; Scaletti F; Gabbiani C; Bianchi L; Bini L; Nobili S; Perrone G; Mini E; Messori L; Modesti A
J Proteomics; 2014 May; 103():103-20. PubMed ID: 24705091
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.
Chappell NP; Teng PN; Hood BL; Wang G; Darcy KM; Hamilton CA; Maxwell GL; Conrads TP
J Proteome Res; 2012 Sep; 11(9):4605-14. PubMed ID: 22900918
[TBL] [Abstract][Full Text] [Related]
4. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.
Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L
Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of cytotoxicity of selected organogold(III) compounds.
Coronnello M; Mini E; Caciagli B; Cinellu MA; Bindoli A; Gabbiani C; Messori L
J Med Chem; 2005 Oct; 48(21):6761-5. PubMed ID: 16220992
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
[TBL] [Abstract][Full Text] [Related]
9. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
11. Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: a joint mass spectrometry and circular dichroism investigation.
Marzo T; Scaletti F; Michelucci E; Gabbiani C; Pescitelli G; Messori L; Massai L
Biometals; 2015 Dec; 28(6):1079-85. PubMed ID: 26453060
[TBL] [Abstract][Full Text] [Related]
12. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
13. Increased glutathione level is not involved in enhanced bleomycin sensitivity in cisplatin-resistant 2780CP cells.
Tanaka T; Kurokawa H; Matsuno K; Matsumoto S; Hayashida Y
Anticancer Res; 2008; 28(5A):2663-8. PubMed ID: 19035292
[TBL] [Abstract][Full Text] [Related]
14. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
15. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B
Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
18. Cellular glutathione level does not predict ovarian cancer cells' resistance after initial or repeated exposure to cisplatin.
Nikounezhad N; Nakhjavani M; Shirazi FH
J Exp Ther Oncol; 2017 May; 12(1):1-7. PubMed ID: 28472558
[TBL] [Abstract][Full Text] [Related]
19. 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds.
Guidi F; Puglia M; Gabbiani C; Landini I; Gamberi T; Fregona D; Cinellu MA; Nobili S; Mini E; Bini L; Modesti PA; Modesti A; Messori L
Mol Biosyst; 2012 Apr; 8(4):985-93. PubMed ID: 22134777
[TBL] [Abstract][Full Text] [Related]
20. NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines.
Ghini V; Sorbi F; Fambrini M; Magherini F
Cells; 2024 Apr; 13(8):. PubMed ID: 38667276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
